Shufeng Xingbi Therapy: Immune and Microbiota Modulation in Allergic Rhinitis Research

Study Background and Research Question

Allergic rhinitis (AR) is a globally prevalent, non-infectious chronic inflammatory disease of the nasal mucosa, characterized by symptoms such as sneezing, nasal congestion, and itching. The pathogenesis centers on an imbalance between T-helper 1 (Th1) and T-helper 2 (Th2) immune responses, with increased IgE and Th2 cytokine production driving persistent inflammation. While conventional treatments—including glucocorticoids and antihistamines—can ease symptoms, their use in children is limited by adverse effects and incomplete modulation of the underlying immune imbalance. Furthermore, emerging evidence links the composition of intestinal microbiota with immune homeostasis and allergy susceptibility, highlighting the need for interventions that simultaneously target immune and microbial dysregulation. Within this context, the reference study (Yan et al., 2025) investigates whether Shufeng Xingbi Therapy (SFXBT), a regimen derived from Traditional Chinese Medicine (TCM), can restore Th1/Th2 equilibrium and beneficially alter gut microbiota in an ovalbumin (OVA)-induced AR rat model.

Key Innovation from the Reference Study

The central innovation of this research is the integration of immune and microbiota endpoints to elucidate the mechanism of SFXBT in AR. While prior work has explored TCM approaches or the role of gut microbiota independently, this study provides direct evidence that SFXBT exerts coordinated effects on both Th1/Th2 immune polarization and the intestinal bacterial community. This dual-action framework advances our understanding of how traditional therapies may operate at the interface of host immunity and microbial ecology.

Methods and Experimental Design Insights

The study employed a controlled, multi-arm rat model to dissect the contributions of SFXBT under different microbiota-modulating conditions:

• 32 male Sprague Dawley rats (6 weeks old) were allocated into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT.
• AR was induced by repeated OVA sensitization and challenge, a standard protocol to recapitulate the allergic phenotype.
• SFXBT was administered both orally (herbal decoction) and intranasally (gel drops), mimicking clinical practice.
• The "antibiotic + SFXBT" arm employed broad-spectrum antibiotics to deplete native microbiota, allowing for assessment of the therapy's interaction with the gut ecosystem.
• Outcomes were assessed at multiple levels: behavioral (AR symptom score), histopathology (nasal mucosa via H&E staining), immunological (serum IgE, IL-4, short-chain fatty acids via ELISA), transcriptional (STAT5, STAT6, GATA3 mRNA by RT-qPCR), and proteomic (Western blot for IL-4, STAT5, STAT6, GATA3).
• Intestinal microbiota composition was profiled by 16S rDNA sequencing of colonic content, enabling taxonomic resolution at phylum and genus levels.

Protocol Parameters

• AR induction: OVA sensitization and challenge over two weeks for robust Th2-skewed inflammation.
• Antibiotic pretreatment: Administered prior to SFXBT to deplete resident gut flora; use when interrogating microbiota-dependent effects.
• SFXBT administration: Combination of oral decoction and nasal gel, daily for 2 weeks; adjust according to study design and animal tolerance.
• Sample collection: Terminal blood, nasal tissue, and colonic content harvested for parallel immunological and microbiota analyses.
• 16S rDNA sequencing: Targeting the V3–V4 region for genus-level resolution.
• Immunoassays: Use ELISA for serum cytokines and SCFAs; RT-qPCR and Western blot for nasal mucosa gene and protein expression.

Core Findings and Why They Matter

The study yielded several interconnected findings (Yan et al., 2025):

• Symptom reduction: Both SFXBT arms (antibiotic + SFXBT, acetic acid + SFXBT) showed significant decreases in AR behavioral scores compared to the OVA-only group (P < 0.01), supported by improved nasal mucosa histology.
• Immune rebalancing: SFXBT reduced serum IgE and IL-4 levels (P < 0.05), key drivers of Th2-dominant inflammation. Downregulation of STAT5, STAT6, and GATA3 at both mRNA and protein levels in nasal tissue indicated a shift away from the Th2 program.
• Microbiota modulation: SFXBT increased the abundance of Firmicutes and decreased Bacteroidetes at the phylum level. At the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were significantly enriched. These taxa are frequently associated with anti-inflammatory and barrier-supportive functions.
• Metabolite restoration: Increased fecal short-chain fatty acids (SCFAs) in SFXBT-treated rats suggest enhanced microbial fermentation capacity, which has immunomodulatory effects through antigen-presenting cell signaling.

Together, these results demonstrate that SFXBT can simultaneously restore Th1/Th2 balance and foster a gut microbiota environment less permissive to allergic inflammation. This mechanistic convergence is particularly relevant for translational allergy research, where both immune and microbial axes are increasingly recognized as therapeutic targets.

Comparison with Existing Internal Articles

Internal resources on Polymyxin B (sulfate) offer complementary perspectives on immune-microbiota interplay in infection and inflammation models. For example, "Polymyxin B (Sulfate): Uniting Antimicrobial Power with Immune Modulation" discusses how Polymyxin B, beyond its bactericidal action against multidrug-resistant Gram-negative bacteria, can promote dendritic cell maturation and alter immune signaling, which is mechanistically analogous to the SFXBT-induced immune rebalancing observed in the AR model. Further, "Polymyxin B Sulfate: Bench Protocols for Gram-Negative Bacteria" details the use of Polymyxin B in sepsis and bacteremia models, where immune-microbiota interactions are central to disease outcome. While Polymyxin B is primarily positioned as an antibiotic for bloodstream and urinary tract infections, its emerging immunomodulatory roles align with the dual-action theme of the SFXBT study, albeit in infectious rather than allergic contexts.

Limitations and Transferability

Several limitations should be considered when interpreting these findings:

• Species and model specificity: The results are based on an OVA-induced rat AR model, which, while widely used, does not fully recapitulate the complexity of human allergic rhinitis or its microbiota-immune nuances.
• Microbiota interventions: The antibiotic and acetic acid arms provide insight into microbiota dependence, but the specific contributions of individual taxa require further mechanistic dissection, potentially via gnotobiotic or monoassociation studies.
• Translation to infection: Although both allergy and infection models involve immune-microbiota crosstalk, the applicability of SFXBT findings to infectious or mixed etiology diseases is undetermined without additional evidence.

Nevertheless, the study establishes robust protocols and endpoints for evaluating immune and microbiota interventions in preclinical allergy models, with conceptual parallels to infection research workflows.

Why this cross-domain matters, maturity, and limitations

Bridging allergic and infectious disease research through immune-microbiota modulation is a timely and promising avenue. The dual focus of SFXBT on immune balance and microbiota echoes the evolving use of agents like Polymyxin B sulfate in Gram-negative bacterial infection research, where immune and microbial parameters are jointly monitored. However, cross-domain generalization should be approached cautiously; direct evidence is needed to support such translation, and interventions validated in one domain (e.g., allergy) may not yield equivalent outcomes in another (e.g., infection or sepsis).

Research Support Resources

Researchers seeking to investigate immune and microbiota interactions in preclinical models can leverage established tools such as Polymyxin B (sulfate) (SKU C3090) for benchmarking Gram-negative bacterial infection, dendritic cell maturation assays, and immune modulation studies. The product’s well-characterized action as a cationic detergent antibiotic and its application in sepsis and bacteremia models are documented in APExBIO and related literature. For protocols integrating immunological and microbiota endpoints, Polymyxin B sulfate offers a reproducible, high-purity standard to support experimental rigor.